• \
`
`'i3
`\
`Asp Tyr Ala Met. se\r Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
`45
`40
`3
`
`•
`
`5
`
`10
`
`15
`
`'20
`
`25y\
`
`30
`
`35
`
`40
`
`45
`
`50
`
`Glu Trp Val Ala
`
`Ile Ser Glu Asn Gly Gly Tyr Thr Arg Tyr
`SS
`60
`
`Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser
`75
`65
`70
`
`Lys Asn Thr Ala Ty Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
`90
`80
`85
`
`Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr
`100
`95
`105
`
`Ala Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
`115
`120
`110
`
`(2) INFORMATION
`
`NO:S :
`
`TERISTICS :
`( i) SEQUENCE C
`amino acids
`(A) LENGTH:
`(B) TYPE : am in acid
`(D) TOPOLOGY :
`inear
`
`(xi) SEQUENCE DESCR PTION : SEQ ID NO : S:
`
`Asp Ile Val Met Thr
`1
`5
`
`ln Ser His LY.s Phe Met Ser Thr Ser Val
`15
`10
`
`Gly Asp Arg Val Ser
`20
`
`le Thr Cys Lys Ala Ser Gln Asp Val Asn
`2S
`30
`
`Thr Ala Val Ala Trp yr Gln Gln Lys Pro Gly His Ser Pro Lys
`40
`4S
`35
`
`Leu Leu Ile Tyr Ser
`so
`
`la Ser Phe Arg Tyr Thr Gly Val Pro Asp
`60
`SS
`
`Arg Phe Thr Gly Asn Arg Ser Gly Thr Asp Phe Thr Phe Thr Ile
`75
`70
`65
`
`Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln
`90
`80
`85
`
`His Tyr Thr Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu
`105
`100
`95
`
`Ile Lys Arg Ala
`109
`
`,,
`
`116 of 1033
`
`BI Exhibit 1002
`
`

`

`•
`
`(2) INFORMATION
`
`~~
`SEQ ID N0 : 6 :
`
`(i ) SEQUENCE C
`( A) LENGTH:
`( B ) TYPE :
`(D ) TOPOLOG
`
`CTERISTICS :
`acids
`
`linear
`
`•
`
`( xi )
`
`Glu Val
`1
`
`SEQ ID N0 : 6 :
`
`Gln Ser Gly Pro Glu Leu Val Lys Pro
`10
`
`Gly
`15
`
`Ala Ser Leu Lys
`
`Ser Cys Thr Ala Ser Cly Phe Asn Ile
`25
`
`Lys
`30
`
`Asp Thr Tyr Ile
`
`Trp Val Lys Gln Arg Pro Clu Gln Cly
`40
`
`Leu
`45
`
`Tyr
`60
`
`Ser
`75
`
`Asp
`90
`
`Tyr
`105
`
`Ser
`120
`
`Ile Tyr Pro Thr Asn Gly Tyr Thr Arg
`55
`
`Asp Pro Lys Phe
`
`Gln Asp
`6:S
`
`Lys Ala Thr Ile Thr Ala Asp Thr
`70
`
`Clu Trp Ile Gly Ar
`so
`I
`I Leu Gln Val Ser Arg Leu· Thr Ser Glu
`
`Ser Asn Thr Ala
`
`Tyf
`
`81
`
`85
`
`Thr Ala Val Tyr
`
`Ala Met Asp Tyr
`
`~r Cys Ser Arg Trp Gly Gly Asp Cly Phe
`
`Gly Gln Gly
`
`Txp
`110
`
`100
`
`Ala Ser
`115
`
`Val Thr Val Ser
`
`(2) INFORMATION FOR SEQ ID N0 : 7 :
`
`( 1) SEQUENCE C~CTERISTICS:
`
`(A) LENGTH: j27 bases
`(B) TYPE: nucleic acid
`I
`(C) STRANDEqNESS : single
`(D) TOPOLOGY : linear
`I
`(xi ) SEQUENCE DESCRIPTION : SEQ ID N0 :7:
`
`TCCGATATCC iGCTGACCCA GTCTCCA 27
`
`(2) (::F:::::::: :~::~:s::c::
`
`(A) LENGTH :I 31 bases
`(B) TYPE : rlucleic acid
`
`5
`
`10
`
`15
`
`~o
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`117 of 1033
`
`BI Exhibit 1002
`
`

`

`•, ;
`
`STRAN 1EDNESS : single
`TOPOLO
`: linear
`
`(C)
`(D)
`
`•
`
`(xi) SEQUENCED SCRIPTION : SEQ IO N0 : 8:
`
`GTTTGATCT CAGCTTGGTA CCXXCXCCGA A 31
`
`(2) INFORMATION FOR SEQ ID N0:9 :
`
`(i) SEQUENCE HARACTERISTICS:
`(A) LENG
`22 bases
`(B) TYPE: nucleic acid
`EDNESS: singl e
`(C) ST
`(0) TOPO GY: linear
`
`(xi)
`
`ESCRIPTION : SEQ IO N0 : 9:
`
`AGGTXXAXC GCAGXAGTCX GG 22
`
`(2) INFORMATION OR SEQ 10 NO:lO :
`
`CTERISTICS :
`(i) SEQUENCE
`(A) LENGTH : 34 bases
`(B) TYPE : ucleic acid
`(C) STRANO DNESS : single
`( D) TOPOLO Y: linear
`
`( xi) SEQUENCE 0
`
`IO NO : lO :
`
`TGAGGAGACG GTGACCGTGG TCCCTTGGCC CCAG 34
`
`(2) lNFORMATIO~ OR SEQ 10 NO:ll:
`
`( i) SEQUENCE
`(A) LENGT
`(B) TYPE:
`(C) STRAN
`(D) TOPO
`
`: 36 bases
`nucleic acid
`EDNESS : single
`Y: linear
`
`(xi) SEQUENCE ESCRIPTION: SEQ ID NO : ll:
`
`AGCCTATCTG CAAATG 36
`
`5
`
`10
`
`15
`
`?Q
`
`25 \t\
`
`30
`
`35
`
`40
`
`45
`
`50
`
`118 of 1033
`
`BI Exhibit 1002
`
`

`

`. --
`
`(2) •
`
`~~
`SEQ ID NO : l2 :
`
`CTERISTICS :
`(i) SEQUENCE C
`(A) LENGTH : 36 bases
`{B ) TYPE :
`cleic acid
`( C) STRANDE NESS : single
`(D) TOPOLOG : linear
`
`(xi) SEQUENCE D
`
`SEQ ID NO : l2 :
`
`GTAGATAAAT CCAAATCTAC AGCCTATCTG CAAATG 36
`
`(2) INFORMATION FR SEQ ID NO : l3 :
`
`(i) SEQUENCE C
`(A) LENGTH
`(B) TYPE :
`(C) STRAND
`( D) TOPOLO
`
`CTERISTICS :
`
`ucleic acid
`DNESS : single
`Y: linear
`
`(xi) SEQUENCE D SCRIPTION : SEQ ID NO:l3 :
`
`GTAGATAAAT CCTCTTCTAC AGCCTATCTG CAAATG 36
`
`(2) INFORMATION
`
`R SEQ IO NO : l4 :
`
`CTERISTICS :
`
`(i) SEQUENCE
`(A) LEN GT
`(B) TYPE: nucleic acid
`(C) s
`EDNESS: single
`(D) TOPO GY : linear
`
`(xi) SEQUENCE ESCRIPTION : SEQ IO NO : l4 :
`
`CTTATAAA
`
`TGTTTCCACC TATAACCAGA AATTCAAGGA TCGTTTCACG 50
`
`ATATCCGT G ATAAATCC 68
`
`(2 ) INFORMATION FOR SEQ ID NO:lS :
`
`(i) SEQUENC CHARACTERISTICS :
`(A) LEN TH : 30 bases
`( B) TYP : nucleic acid
`(C ) ST
`DEDNESS : s ingle
`( D) TO OLOGY : linear
`
`5
`
`10
`
`15
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`119 of 1033
`
`BI Exhibit 1002
`
`

`

`.• --
`
`•
`
`CTATACCTCC GTCTGCATT CTGGAGTCCC 30
`
`(2) INFORMATION
`
`SEQ ID NO:l6:
`
`(i) SEQUENCE C
`CTERISTICS:
`07 amino acids
`(A) LENGTH:
`(B) TYPE: am~o acid
`(0) TOPOLOGY: linear
`
`(xi) SEQUENCE DESC IPTION: SEQ ID NO : l6 :
`
`Asp Ile Gln Met Thr Gln Thr Thr Ser. Ser Leu Ser Ala Ser Leu
`s
`15
`1
`10
`
`Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg
`20
`25
`30
`
`Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys
`35
`40
`45
`
`Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser
`so
`55
`60
`
`Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile
`65
`70
`75
`
`Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln
`80
`85
`90
`
`Cly Asn Thr Leu Pro, Trp Thr Phe Ala Gly Gly Thr Lys Leu Glu
`95
`100
`105
`
`(2) INFORMATION FOR SEQ ID NO : i·7 :
`
`I
`Ile ~~;
`( 1) SEQUENCE C~CTERISTIC·~ :
`
`(A) LENGTH : /107 amino acids
`(B) TYPE : amino acid
`'
`I
`.
`(D) TOPOLOGY : linear
`(xi) SEQUENCE DESCRIPTION : SEQ ID N0 : 17:
`I
`Ls
`
`Asp Ile Gln Met 'JJhr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val
`1
`10
`15
`
`Gly Asp Arg Val
`
`r Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg
`\ 20 .
`25
`30
`
`5
`
`10
`
`15
`
`?Q
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`120 of 1033
`
`BI Exhibit 1002
`
`

`

`•
`
`Asn Tyr Leu Asn
`
`•
`
`Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
`40
`45
`
`Leu Leu Ile Tyr
`
`Thr Ser Arg Leu Glu Ser Gly Val Pro Ser
`55
`60
`
`Arg Phe Ser Gly
`
`Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile
`70
`75
`
`Ser Ser Leu Gln Pr Glu Asp _Phe Ala Thr Tyr Tyr Cys Gln Gln
`8
`85
`90
`
`Gly Asn Thr Leu Pr Trp Tilr Phe Gly Gln Gly Thr Lys Vai Glu
`9
`105
`100
`
`Ile Lys
`107
`
`(2) INFORMATION
`
`EQ ID NO:l8 :
`
`CTERISTICS :
`(i) SEQUENCE C
`(A) LENGTH: 1 · 7 amino acids
`(B) TYPE : a.mi o acid
`(D) TOPOLOGY : linear
`
`(xi)
`
`IPTION : SEQ ID NO : l8 :
`
`5
`
`10
`
`15
`
`25
`
`30 ~\
`
`Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val
`1
`5
`10
`15
`
`Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser
`20
`25
`30
`
`35
`
`40
`
`45
`
`50
`
`Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
`40
`35
`45
`
`Leu Leu Ile Tyr
`
`Ala ~er Ser Leu Glu Ser Gly Val Pro Ser
`55
`60
`
`Arg Phe Ser Gly
`
`Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
`70
`75
`
`Ser Ser Leu Gln
`
`Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
`85
`90
`
`Tyr Asn Ser Leu
`
`Trp Thr Phe Gly Gln Gly Thr Lys Val Glu
`100
`105
`
`Ile Lys
`107
`
`121 of 1033
`
`BI Exhibit 1002
`
`

`

`.• --. , -
`
`-
`
`-
`
`-
`
`•
`
`'\ ~
`(2) INFORMATION FOR SEQ ID NO;l9 :
`
`(i) SEQUENCE C
`(A) LENGTH:
`(B)
`(D)
`
`CTERISTICS:
`9 amino acids
`
`(xi)
`
`SEQ ID N0:19 :
`
`Glu Val Gln Leu
`1
`
`ln Ser Gly Pro Glu Leu Val Lys Pro Gly
`10
`15
`
`Ala Ser Met Lys Ile er Cys Lys Ala Ser Gly Tyr Ser Phe Thr
`30 '
`20
`25
`
`Gly Tyr Thr Met Asn
`35
`
`rp Val Lys Gln Ser His Gly Lys Asn Leu
`40
`45
`
`Glu Trp Met Gly Leu
`50
`
`le Asn Pro Tyr Lys Gly Val Ser Thr Tyr
`55
`60
`
`Asn Gln Lys Phe
`
`Arg Phe Thr Ile Ser Lys Ala Thr Leu
`75
`70
`
`Thr Val Asp Lys Ser S r Ser Thr Ala Tyr Leu Met Glu Leu Leu
`90
`85
`80
`
`Asn Ser Leu Thr Ser
`95
`
`Asp Ser Ala Val Tyr Tyr Cys Ala Arg
`100
`105
`
`Ser Gly Tyr Tyr
`
`Ala Gly Thr Thr
`
`(2) INFORMATION FOR
`
`Ser Asp Trp Tyr Phe Asp Val Trp Gly
`115
`120
`
`r Val Ser Ser
`129
`
`(i) SEQUENCE C
`(A) LENGTH :
`(B) TYPE: ami
`(D) TOPOLOGY: linear
`
`TERISTICS :
`acids
`
`(xi) SEQUENCE DESC IPTION : SEQ ID N0:20:
`
`Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
`l
`15
`10
`5
`
`Gly Ser Leu Arg Le Ser Cys Ala Ala Ser Gly Tyr Ser Phe Thr
`25
`30
`2\
`Asn Trp
`35
`
`Val Arg Gln Ala Pro Gly Lys Gly Leu
`40
`45
`
`Gly Tyr Thr Met
`
`5
`
`10
`
`15
`
`.,0
`
`25
`
`30 v\
`
`35
`
`40
`
`45
`
`50
`
`122 of 1033
`
`BI Exhibit 1002
`
`

`

`•
`
`(oo
`
`· -
`
`Glu Trp Val Ala Leu Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr
`so
`55
`60
`
`5
`
`10
`
`15
`
`?O
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`Asn Gln Lys Phe Lys Asp Arg Phe Thr Ile Ser Val Asp Lys Ser
`65
`70
`75
`
`Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
`80
`85
`90
`
`Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly Asp Ser
`95
`100
`lOS
`
`Asp Trp Tyr Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val
`115
`110
`120
`
`Ser Ser
`122
`
`(2) INFORMATION
`
`(1) SEQUENCE C
`(A) LENGTH:
`(B)
`(D)
`
`CTERISTICS :
`2 amino acids
`o acid
`linear
`
`(xi)
`
`IPTION: SEQ ID NO: 21 :
`
`Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
`s
`1
`10
`lS
`~\ Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
`
`20
`
`25
`
`30
`
`Ser Tyr Ala Met Ser Trp Val Arg Gl n Ala Pro Cly Lys Cly Leu
`3S
`40
`45
`
`Glu Trp Val Ser Val Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr
`so
`. 60
`SS
`
`Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
`75
`70
`6J
`Lys Asn Thr Leu Ty Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
`80
`85
`90
`
`Thr Ala Val Tyr Ty Cys Ala Arg Gly Arg Val Gly Tyr Ser Leu
`9
`100
`105
`
`Ser Gly Leu Tyr As Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
`11 1
`llS
`120
`\
`
`Ser Ser
`122
`
`123 of 1033
`
`BI Exhibit 1002
`
`

`

`···--
`
`,_
`
`•
`
`1° I
`(2) INFORMATION FOR SEQ ID N0:22 :
`
`(i) SEQUENCE C
`(A) LENGTH:
`(B)
`(D)
`
`CTERISTICS:
`acids
`
`(xi)
`
`SEQ ID N0:22 :
`
`Gln Val Gln Leu
`1
`
`Gln Ser Gly Pro Glu Leu Val Lys Pro Gly
`10
`15
`
`Ala Ser Val Lys
`
`Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr
`25
`30
`
`Glu Tyr Thr Met His Trp Met Lys Gln Ser His Gly Lys Ser Leu
`35
`40
`45
`
`Glu Trp Ile Gly Cly Phe Asn Pro Lys Asn Gly Gly Ser Ser His
`50
`55
`60
`
`Asn Gln Arg Phe Met Asp Lys Ala Thr Leu Ala Val Asp Lys Ser
`65
`70
`75
`
`Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp
`80
`85
`90
`
`Ser Gly Ile Tyr Tyr Cys Ala Arg Trp Arg Gly Leu Asn Tyr Gly
`95
`100
`105
`
`110
`
`115
`
`120
`
`Y" Phe Asp Val Arg Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val
`
`Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
`125
`130
`135
`
`Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Cly
`140
`145
`150
`
`Cys Leu Val Lys Asp yr Phe Pro Glu Pro Val Thr Val Ser Trp
`155
`160
`165
`
`Asn Ser Gly Ala Leu
`170
`
`r Ser Gly Val His Thr Phe Pro Ala Val
`175
`180
`
`Leu Gln Ser Ser Cly eu Tyr Ser Leu Ser Ser Val Val Thr Val
`185
`190
`195
`
`Pro Ser Ser Ser Leu
`200
`
`ly Thr Gln Thr Tyr Ile Cys Asn Val Asn
`205
`210
`
`His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
`215
`220
`225
`
`5
`
`10
`
`15
`
`-'l
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`124 of 1033
`
`BI Exhibit 1002
`
`

`

`••
`
`(0 '-
`
`· ·-- I
`
`- -- ......... ~
`
`-
`
`Ser Cys Asp Lys Th His Thr Cys Pro Pro Cys Pro Ala Pro Glu
`235
`240
`23
`
`5
`
`10
`
`15
`
`... ')
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`Leu Leu Gly Gly Pr Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
`24
`255
`250
`
`Asp Thr Leu Met Il Ser Arg Thr Pro Glu Val Thr Cys Val Val
`26
`265
`270
`
`Val Asp Val Ser Hi Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
`27
`280
`285
`
`Val Asp Gly Val Gl Val His Asn Ala Lys Thr Lys Pro Arg Glu
`29
`295
`300
`
`Glu Gln Tyr Asn
`
`Thr Tyr Arg Val Val Ser Val Leu Thr Val
`310
`315
`
`Leu His Gln Asp
`
`Leu Asn Gly Lys Glu Tyr Lys Cys .Lys Val
`325
`330
`
`Ser Asn Lys Ala
`
`Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
`340
`345
`
`Ala Lys Gly Gln
`
`Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
`355
`360
`
`Ser Arg Glu Glu
`
`Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
`370
`375
`
`~\ Val Lys Gly Phe Ty Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
`
`38
`
`385
`
`390
`
`Asn Gl y Gln Pro Gl Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
`39
`400
`405
`
`Asp Ser Asp Gly S r Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
`415
`420
`4 0
`
`Lys Ser Arg Trp
`
`n Gln Gly Asn Val Phe Ser Cys Ser Val Met
`5
`430
`435
`
`His Glu Ala Leu
`
`Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
`445
`450
`
`Ser Pro Gly Lys
`454
`
`(2) INFORMATION OR SEQ ID NO : 2 3 :
`
`( 1 ) SEQUENCE
`- 557 amino acids
`(A) LENG
`(B) TYPE : am ino acid
`{D) TOPO ~_ GY : linear
`
`125 of 1033
`
`BI Exhibit 1002
`
`

`

`•
`
`\
`I
`(xi) SEQUENCE DESCR I TION: SEQ ID N0:23 :
`
`10-3
`
`.l/Uv 7L' U.Jl.C.O
`
`5
`
`10
`
`15
`
`·o
`
`25
`
`His His Gln Val Gln L u Gln Gln Ser Gly Pro Glu Leu Val Lys
`l
`5
`10
`15
`
`Pro Gly Ala Ser Val L s Ile Ser Cys Lys Thr Ser Gly Tyr Thr
`20
`25
`30
`
`Phe Thr Glu Met Gly T p Ser Cys Ile Ile Leu Phe Leu Val Ala
`40
`35
`45
`
`Thr Ala Thr Gly Val.H s Ser Glu Val Gln Leu Val Glu Ser Gly
`so
`55
`60
`
`Gly Gly Leu Val Gln
`65
`
`Gly Gly Ser Leu Arg Leu Ser Cys Ala
`70
`75
`
`Thr Ser Gly Tyr Thr
`80
`
`Glu Tyr Thr Met His Trp Met Arg
`85
`90
`
`Gln Ala Pro Gly Lys
`95
`
`ly Leu Glu Trp Val Ala Gly Ile Asn Pro
`100
`105
`
`Lys Asn Gly Gly Thr er His Asn Gln Arg Phe Met Asp Arg Phe
`115
`120
`110
`
`Thr Ile Ser Val Asp
`125
`
`30 \/\ Asn Ser Leu Arg Ala
`
`140
`
`Trp Arg Gly Leu Asn
`155
`
`Ser Thr Ser Thr Ala Tyr Ket Gln Ket
`130
`135
`
`Asp Thr Ala Val Tyr Tyr Cys Ala Arg
`145
`150
`
`Gly Phe Asp Val Arg Tyr Phe Asp Val
`160
`165
`
`35
`
`40
`
`45
`
`50
`
`Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
`170
`175
`180
`
`Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser
`195
`185
`190
`
`Glu Ser Thr Ala
`
`Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
`205
`210
`
`Glu Pro Val Thr
`
`Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
`220
`225
`
`Val His Thr Phe
`
`Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
`235
`240
`
`Leu Ser Ser Val v
`2
`
`Thr Val Thr Ser Ser Asn Phe Gly Thr Gln
`250
`255
`
`126 of 1033
`
`BI Exhibit 1002
`
`

`

`•
`
`Thr Tyr Thr Cys Asn
`260
`
`'\
`
`.•. ~~ ,~ . "'""'""''-V
`
`I O"i
`l Asp His Lys Pro Ser Asn Thr Lys Val
`265
`270
`
`Asp Lys Thr Val Glu
`275
`
`rg Lys Cys Cys Val Thr Cys Pro Pro Cys
`280
`285
`
`Pro Ala Pro Glu Leu
`290
`
`u Gly Gly Pro Ser Val Phe Leu Phe Pro
`295
`300
`
`Pro Lys Pro Lys Asp
`305
`
`r Leu Met Ile Ser Arg Thr Pro Glu Val
`310
`315
`
`Thr Cys Val Val Val sp Val Ser His Glu Asp Pro Glu Val Lys
`320
`325
`330
`
`Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val
`335
`340
`345
`
`Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
`350
`355
`360
`
`Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
`365
`370
`375
`
`Pro Glu Val Gln
`
`Asn Trp Tyr Val Asp Gly Met Glu Val His
`385
`390
`
`Asn Ala Lys Thr
`
`Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe
`400
`405
`
`Arg Val Val Ser
`
`Leu Thr Val Val His Gln Asp Trp Leu Asn
`415
`420
`
`v\
`
`Gly Lys Glu Tyr L~s Cys Lys Val Ser Asn Lys Gly Leu Pro Ala
`4 5
`430
`435
`I Ile Ser Lys Thr
`
`Thr
`4r0
`Pro Gln Val Tyr 'lihr Leu Pro Pro Ser Arg Glu Glu Mee Thr Lys
`4155
`460
`465
`
`Pro Ile Glu Lys
`
`Lys Gly Gln Pro Arg Glu
`445
`450
`
`Asn Gln Val Ser
`
`Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
`480
`475
`
`leu
`I 470
`i
`Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
`I rss
`490
`495
`Pro Pro Met Leu Asp Ser
`500
`505
`I
`I
`Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
`525
`515
`520
`
`Tyr Lys Thr Thr
`
`I
`
`Asp Gly Ser Phe
`
`Phe
`510
`
`5
`
`10
`
`15
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`127 of 1033
`
`BI Exhibit 1002
`
`

`

`•
`
`Asn Val Phe Ser Cys
`530
`
`··-- I ' - • "-'~L-V
`
`IQ )
`
`I
`I
`Ser Val Met His Glu Ala Leu His Asn His
`53S
`S40
`
`5
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`Tyr Thr ~ln Ly s Ser Leu Ser Leu Ser Pro Gly Lys
`S45
`550
`
`555
`
`(2) INFORMATION FOR EQ ID N0:24 :
`
`CTERISTICS :
`(i) SEQUENCE C
`14 amino acids
`(A) LENGTH :
`(B) TYPE : am no acid
`(D) TOPOLOGY: linear
`
`(xi)
`
`SEQ ID N0:24:
`
`Asp Val Gln Met
`l
`
`Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu
`10
`15
`
`Gly Asp Arg Val
`
`Ile Asn Cys Arg Ala Ser Gln Asp Ile Asn
`25
`30
`
`Asn Tyr Leu Asn
`
`Ty_r Gln Gln Lys Pro Asn Gly Thr Val Lys
`40
`45
`
`Leu Leu Ile Tyr
`
`Thr Ser Thr Leu His Ser Gly Val Pro Ser
`SS
`60
`
`Arg Phe Ser Gly
`
`Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile
`70
`75
`
`~\
`
`Ser Asn Leu Asp
`
`Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln
`85
`90
`
`Gly Asn Thr Leu
`
`ro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu
`9S
`100
`105
`
`Ile Lys Arg Thr al Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
`110
`115
`120
`
`Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu
`12S
`130
`135
`
`Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val
`140
`145
`150
`
`Asp Asn Ala Le · Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu
`165
`155
`160
`
`Gln Asp Ser L s Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr
`17S
`180
`170
`
`Leu_ Ser Lys A a Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu
`190
`195
`185
`
`I
`
`128 of 1033
`
`BI Exhibit 1002
`
`

`

`• • , ~- 1 1 . . · - - .. -
`
`-
`
`D ~ro Val Thr Lys Ser Phe Asn
`
`205
`
`210
`
`\ u ~er se
`
`1r
`
`•
`
`Val Thr His Gln Gly
`200
`
`Arg Gly Glu Cys
`214
`
`(2) INFORMATION FOR S
`
`ID N0 : 25 :
`
`( i) SEQUENCE CHARAC ERISTICS :
`(A) LENGTH: 233 amino acids
`( B) TYPE : amino acid
`( D) TOPOLOGY : linear
`
`(xi) SEQUENCE DESCRIIPTION: SEQ ID N0 : 25 :
`
`Met Cly Trp Ser Cys I e Ile Leu Phe Leu Val Ala Thr Ala Thr
`1
`5
`10
`15
`
`Gly Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
`20
`25
`30
`
`Ser Ala Ser Val Cly
`35
`
`.sp Arg Val Thr Ile Thr Cys Arg Ala Ser
`40
`45
`
`Cln Asp Ile Asn Asn yr Leu Asn Trp Tyr Gln Gln Lys Pro Cly
`50
`55
`60
`
`Lys Ala Pro Lys Leu eu Ile Tyr Ty r Thr Se r Thr Leu His Ser
`65
`70
`75
`
`Gly Val Pro Ser Arg he Ser Cly Ser Gly Ser Gly Thr Asp Tyr
`80
`85
`90
`
`Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Th.r Tyr
`95
`100
`105
`
`Tyr Cys Gln Gln Cly Asn Thr Leu Pro Pro Thr Phe Cly Cln Cly
`110
`115
`120
`
`Thr Lys Val Glu Il
`12
`
`Lys Arg Thr Val Ala Ala Pro Ser Val Phe
`130
`135
`
`Ile Phe Pro Pro
`
`Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser
`145
`150
`
`Val Val Cys Leu
`
`0
`
`175
`
`180
`
`5
`
`10
`
`15
`
`25
`
`30 \'\
`
`35
`
`40
`
`45
`
`50
`
`~=[
`Asn As n Phe Tyr Pro Arg Glu Ala Lys Val
`~5
`160
`165
`Gln Trp Lys Val i,p Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
`
`Ser Val Thr Glu
`
`· ln Asp Ser Lys As p Ser Thr Tyr Ser Leu Ser
`190
`195
`
`(Las
`
`129 of 1033
`
`BI Exhibit 1002
`
`

`

`•
`
`lo~ .
`Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
`210
`205
`200
`
`• "
`
`5
`
`(\ Tyr Ala Cys Glu Val
`
`215
`
`r His Gln Gly Leu Ser Ser Pro Val Thr
`225
`220
`
`Lys Ser 'Phe Asn Arg
`230
`
`Cys
`233
`
`'
`
`'
`
`I
`
`I
`
`'
`
`130 of 1033
`
`BI Exhibit 1002
`
`

`

`-I
`
`\:1'
`
`.......
`
`l)O/EO BIBLI OGRAPHI C L.•ATA ENTRY
`
`l 7
`RECEIPT D1.;T E ~
`l ~ /
`IA FILING !.!•ATE:
`1)6 I 15
`y
`DELAY WAIVED
`( ~· /N) :
`y
`t•EMANl.l RECE I VEl• (V/NJ :
`PRI(IRJTY DA rE :
`(Ii:.
`I 14
`us l:OES I GNI~ TEV ONLY (Y/N ):
`cou11nRY:
`
`I 93
`I n
`
`I 91
`N
`usx
`
`1.1 8
`Sl::RI1:.1.. NUMBER :
`:462(1€ .
`I
`IA NUMBER:
`PCT/ ~692 I 05126
`~ AMILY NAME:
`CARTER
`PAUL .J.
`G ! VEN l'llAME :
`y
`PRIORI rv CLAIME.y
`iY/N):
`NO BAS IC FEE <YIN>:
`1\1
`ATTORNEY DOCKET NUMBER:
`709P1
`CORRESF'ONDENTS NAME/ADDRESS:
`CAROLYN R. A~LER
`I NC .
`GiENENTECH .
`460 POI~r SAN BRUN0 BOULEVARD
`SOUTH SAN FRANCISCO. CALIFORNIA 94(180
`
`APPLICATION TITLES:
`METHOD FOR l'IAKlNG HUMAN I ZED P1NTIBOL>IE$
`
`-~"' .·
`
`131 of 1033
`
`BI Exhibit 1002
`
`

`

`BAR CODE LABEl
`
`I llll\lllllll l!ll lllll lllll!11111111 ltlll llll llll
`
`U.S. PA'TENT APPLICATION
`
`SERIAL NUMBER
`
`08/146,206
`
`FILING DATE
`
`Cl.ASS
`
`GROUP ART UNIT
`
`11/17/93
`
`435
`
`1804
`
`PAUL J. CARTER, SAN FRANCISCO, CA; LEONARD G. PRESTA, SAN FRANCISCO, CA.
`
`••CONTINUING DATA*********************
`THIS APPLN IS A 371 OF
`VERIFIED
`
`/ US92/05126 06/15/92
`
`**FOREIGN/PCT APPLICATIONS************
`VERIFIED
`PCT
`PCT/\JS92/05•126
`
`06/15/92
`
`STATE OR
`COUNTRY
`
`SHEETS
`DRAWING
`
`TOTAL
`CLAIMS
`
`INDEPENDENT
`CLAIMS
`
`FILING FEE
`RECEIVED
`
`ATTORNEY DOCKET NO.
`
`CA
`
`9
`
`18
`
`9
`
`Sl,592.00
`
`709Pl
`
`II)
`~
`~
`~
`
`JANET E. HASAK
`GENENTECH, INC.
`460 POINT SAN BRUNO BOULEVARD
`SOUTH SAN FRANCISCO, CA 94080-4990
`
`IMMUNOGLOBULIN VARIANTS
`
`This is to certify that annexed hereto is a true copy from the re1:;ords of the United States
`Patent and Trademark Office of the application which is identifo:td above.
`By authority of the
`COMMISSIONER OF PATENTS AND TRADEMARKS
`
`Date
`
`Certif ying Officer
`
`132 of 1033
`
`BI Exhibit 1002
`
`

`

`_ .....
`
`PATENT APPLICATION SERIAL NO.
`
`U. S. DEPARTMENT OF COMMERCE
`PATENT AND
`'fRADEMARK OFFICE
`FEE RECORD SHEET
`
`I ! ! . • ,, . · •• ·:
`
`(.:· .. '\·+· · ,
`
`....
`
`MR1 .. ,
`
`PT0- 1556
`(5/87)
`
`.-.....
`
`.... - -
`
`·-
`
`133 of 1033
`
`BI Exhibit 1002
`
`

`

`PATENT APPLICATION FEE DETERMINATION RECORD
`Effective October 1, 1992
`
`Application.or Docket Number
`
`CLAIMS AS FILED - PART I
`Column 1
`NUMBER FILED
`
`Column 2
`NUMBER EXTRA
`
`FOR
`
`BASIC FEE
`
`TOTAL CLAIMS
`
`INDEPENDENT CLAIMS
`
`CJ
`MULTIPLE DEPENDENT CLAIM PRESENT
`
`minus 3 = * b
`
`"' 11 lhe difference in column 1 is less !hen zero, enier ·o· in column 2
`
`SMALL ENTITY
`
`OTHER THAN
`OR SMALL ENTITY
`
`RATE
`
`FEE
`1.. 7 5
`$35'1!66
`
`RATE
`
`FEE
`C f / -
`. :; u
`
`OR
`
`$~
`
`x$11=
`x 37:::
`+115::
`
`TOTAL
`
`OR x$22=
`OR x 74=
`OR +230=
`
`OR TOTAL
`
`CLAIMS AS AMENDED - PART II
`(Column l)
`(Column2)
`
`(Column3)
`
`SMALL ENTITY
`
`OR
`
`OTHERntAN
`SMAU ENTITY
`
`CLAIMS
`REMAINING
`AFTER
`AMENDMENT
`•
`
`Total
`Independent •
`
`HIGHEST
`NUMBER
`PREVIOUSLY
`PAID FOR
`
`...
`• ••
`
`Minus
`
`Minus
`
`FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM
`
`=
`
`=
`
`PRESENT
`EXTRA
`
`RATE
`
`ADDI-
`TIONAL
`FEE
`
`ADDI-
`RATE TIONAL
`FEE
`
`PRESENT
`EXTRA
`
`RATE
`
`ADDI-
`TIONAL
`FEE
`
`ADDI-
`RATE TIONAL
`FEE
`
`(Column l)
`
`CLAIMS
`REMAINING
`AFTER
`
`•
`Total
`Independent •
`
`Minus
`
`Minus '
`
`(Column 2)
`
`(Cofumn3)
`
`HIGHEST
`NUMBER
`PREVIOUSLY
`PAID FOR
`••
`•••
`
`=
`
`=
`
`FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM
`
`(Column 1)
`
`(Column2)
`
`(Column3)
`
`x$11 ==
`
`x 37=
`
`+ 115=
`
`TOTAL
`A DDIT. FEE
`
`OR
`
`OR
`
`x$22=
`
`x 74=
`
`OR
`OR +230=
`TOTAL
`OR
`ADDIT. FEE
`
`x$11 =
`
`x 37=
`
`+ 115=
`TOTAL
`A DDIT. FEE
`
`OR x$22=
`OR
`
`x 74=
`
`OR
`OR +230=
`TOTAL
`OR
`AODIT. FEE
`
`•
`
`Total
`Independent *
`
`Minus
`
`Minus
`
`HIGHEST
`NUMBER
`PREVIOUSLY
`PAID FOR
`••
`
`•••
`
`PRESENT
`EXTRA
`
`RATE
`
`ADDI-
`TIONAL
`FEE
`
`ADDI·
`RATE TIONAL
`FEE
`
`x$11 =
`
`x 37=
`
`OR x$22=
`OR
`x74=
`
`OR
`
`FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM
`• II the entry in column 1 is less than the entry in oolumn 2, write •o• in oolumn 3.
`•• If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enler ·20·.
`···II !he "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter ·a·.
`The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.
`FORM PT0-875
`fAev.10·92)
`
`+115=
`
`TOTAL
`ADDIT. FEE
`
`OR +230=
`
`TOTAL
`OR
`AODIT. FEE ___ ..
`
`Patent and T...dcmaitc Office; U.S. DEPARTMENT OF COMMEP
`
`134 of 1033
`
`BI Exhibit 1002
`
`

`

`MULTIPLE DEPENllENT CLAIM
`FEE CALCULATION SHEET
`(FOR USE WITH FOR..\! P'T'0-875)
`
`AS FILED
`
`AF TEA
`AFTER
`hi AMENDMENT 2nd AMENDMENT
`
`rLAIMS
`
`SERIAL NO.
`
`APPLICANflSJ
`
`FILING DATE
`
`.
`
`•
`
`•
`
`IND.
`I
`
`f
`
`I
`
`I
`
`I
`I
`I
`I
`I
`
`l
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`29
`30
`31
`32
`33
`34
`35
`3€
`37
`38
`39
`40
`41
`42
`43
`44
`45
`46
`47
`48
`49
`50
`'
`l
`TOTAL
`~J
`IND.
`TOTAL 1C
`DEP.
`TOTAL J.'i
`CLAIMS
`PT0·131l0 (3-78)
`
`DEP.
`
`IND.
`
`DEP.
`
`IND.
`
`DEP.
`
`IND.
`
`DEP.
`
`IND.
`
`DEP.
`
`IND.
`
`DEP.
`
`I
`I
`I
`I
`I
`
`I
`
`,,,,,
`
`I
`
`I
`
`·-
`
`.J
`
`.J
`
`.J
`
`-
`
`51
`52
`53
`54
`55
`56
`57
`58
`69
`GO
`61
`62
`63
`64
`66
`66
`67
`68
`69
`70
`71
`72
`73
`74
`75
`76
`77
`78
`79
`80
`81
`82
`83
`84
`85
`86
`87
`88
`89
`90
`91
`92
`93
`94
`95
`96
`97
`98
`99
`100
`TOTAL
`IND.
`TOTAL
`DEP.
`TOTAL
`CLAIMS
`
`~
`
`-
`
`_J
`
`J -.J
`
`•MAY BE l
`
`tlD Jo'OR ADD/'l'IO/<;AL CLAIMS 01! AMENDMENTS
`
`U.S. DEPARTMENT o f COM MGnCE
`Patont and Tredoninr" Offlco
`
`135 of 1033
`
`BI Exhibit 1002
`
`

`

`'
`PA.NT COOPERATION TREATY.
`13 Rec'd PCT/r~ ~ 17 FEB 1993
`PCT
`
`To:
`
`From the INTERNATIONAL BUREJ'.>,U
`
`NOTIFICATION OF ELECTION
`
`(PCT Rule 6 1.2)
`
`Date of mailing :
`09 February 1993 (09.02.93)
`
`International application No.:
`PCT/US92/05126
`
`International filing date:
`15 June 1992 (15.06.92)
`
`Applicant:
`
`CARTER, Paul, J . et al
`
`United States Patent and Tradem ark
`Office
`Washington, D.C.
`
`in its capacity as elected Office
`
`Applicant's or agent's file reference:
`709P1
`
`Priority date:
`
`14 June 1991 (14.06.91)
`
`1. The designated Office is hereby notified of its election made:
`
`[8J in the demand filed with the International preliminary Examining Authority on:
`07 January 1993 (07.01.93)
`
`D in a notice effecting later election filed with the International Bureau on:
`
`2. The election [8J was
`D was not
`
`m'11e before the expiration of 19 months from the priority date.
`
`The International Bureau of WIPO
`34, chemin des Colombettes
`1211 Geneva 20, Switzerland
`
`Facsimile No. : (41 -22) 740. 14.35
`Form PCTllB/331(July1992)
`
`Authorized officer:
`
`J. Leitao
`• Telephone No.: (41-22) 730.91 .11
`
`000132072
`
`136 of 1033
`
`BI Exhibit 1002
`
`

`

`9'- ENT COOPER ATION T R EAT;?.
`
`PCT
`
`REC'D 2 3 SEP. 199 3
`... ,,.....,._
`_.,
`;
`t
`·.J I
`
`(l'CT /\rticlc .16 and Ruic 70)
`
`··i\pplicanl's or itgenl's file rerercncc
`
`709Pl
`International :1pplicittion No.
`
`fO U fURTllEU ACTION
`
`Sci? N otilicallon or Tr itnsmitlitl of I ntcrnationitl
`Preliminary J:.xami11ation Report (l'orm PCT/ll'Ei\/416)
`
`I nll?rn:llional f11ing d;1tc ( day/m"nth/ycar)
`
`f'riority dillc ( dny/mo11th/ycar)
`
`PCT/US 92/ 05126
`15/06/1992
`International Patent Classilication (1 PC) or national clas~iftcitliun and I l'C
`
`14/06/1991
`
`Applicant
`
`GENENTECH, INC. et al.
`
`C12Nl5/13
`
`1.
`
`2.
`
`This international preliminary examination report has l>cen prepared by this International Preliminary r:.xamining
`Authority and is transmitted lo the :1.pplicanl according to i\rticl<? 36.
`
`This REPORT consi~L( of a total o f __ 8~-- ~heels.
`00 This report is also accompanied by ANNEXES, i.<? .. sheets of the description, claim~ itnd/or drnwings amended
`
`during international preliminary examination and/or containing rcctilications made before this _Aut~ority.
`
`These annexes consists of a lotal of
`
`sheets.
`
`3.
`
`This report contains indications and corresponding pages relating lo the following items:
`
`l3<1sis of the reporl
`
`Priority
`
`'(2g
`II 0
`"'®
`1vO
`Lack of unity of invention
`v~
`Reasoned statement with rcg:trd to novelty, invenLive srep or imlustri;il ;1pplicitbility;
`cilati<?ns ;ind explanations supporting such ~litlcmonl
`
`Non-establishment of opinion with regard Lo novclly, inventive step :tntl industrial applicability
`
`v10
`VII 0
`VII I D
`
`Certain documenl5 cited
`
`Cert;iin defects in the international ;ipplicallon
`
`Certain observations on the intcrn~tional :1.rplic:1.tic-11
`
`U<11e of submission of the demand
`
`Ditte or completion of thi~ .report
`
`07/01/1993
`
`Name and mailing add_re5s or lhc ll'f"'-i
`
`.,I) European P;itcnL Office, Erh!\rd1.s1r;1sse 27
`
`W-8000 Munich 2
`Tel. ( + 49-89) 2399-0,.Tx: S 236S6 epmu <.I
`F:1.x: ( + 49-89) 2399-4465
`
`2 o. 09. 93
`
`/\ulhori?.cd officer 11·
`
`- p ~---- - c-:)
`C. Genntnar•o ·
`
`·• l•orm l'Cl / IPP.i\/409 (cover sheet) (July 1992) P20476
`
`(l 4/06/ 1993)
`
`137 of 1033
`
`BI Exhibit 1002
`
`

`

`••
`
`Intern. application No.
`PCT/US92/05126
`
`INTERNATIONAL PRELIMINARY EXAMINATION REPORT
`
`r. Basis of the report
`
`1,. This report has been dra1m up on the basis of:
`
`[ ) the international application as originally filed.
`
`[x) the description, pages 1-107 _ _ _ _ _ _ _ _ _ _ _ , as originally filed,
`pages
`·, filed with the demand,
`pages
`, filed with the letter of - - - - -
`, filed with the letter of -----
`pages
`
`..,.-----------
`[x] the claims, No. 10-17
`, as originally filed,
`No.
`, as amended under Article 19,
`No.
`, filed with the demand,
`No. 1-9, 18, 19
`, filed with the letter of 12. 06. 93,
`Ho.
`, filed with the letter of ____ _
`
`[x } the drawings, sheets/fig 1/9 -
`s bee ts/fig
`sheets/fig
`sheets/fig
`
`9 /9
`
`---------
`, as originally filed,
`· ·, filed with the demand,
`, filed with the letter of _ _ _ _ _
`, filed with the letter of - - - - -
`
`2. The amendments have resulted in the cancellation of: pages: - - - - - - - - - - - - - (cid:173)
`sheets of drawings/fiqures No.: - - - - - - - - - - - - - -
`
`3. ( ) This report bas been established as if (some of) the amendments bad not been made, since they have been
`consid~ed to go beyond the disclosure as filed:
`
`4. Additional observations, if necessary:
`
`Pon PCT/lPEA/409 (sheet 1) (July 1992)
`
`138 of 1033
`
`BI Exhibit 1002
`
`

`

`INTERNATIONAL PRELIMINARY EXAMINATION REPORT
`
`Intern. application Ho.'
`PCT/US92/05126
`
`III. lfon-establishl.ent of opinion with reqard to novelty, inventive step and industrial applicability
`
`The .questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or
`to be industrially applicable have not been and will not be ell'.amined in respect of:
`
`[ J the entire international application,
`
`[x) claims Nos. 1 7, 18 ----------------------
`because:
`relate
`[x] the said internaHonal application, or the said cla.ims Nos. 17. , 18
`to the followinq subject matter which does not require an international preliminary ell'.am.ination (specify):
`
`Claims 17 is directed to a mere presentation of informa(cid:173)
`tion, namely the translation of the information inherent
`in an amino acid sequence into a message or a language
`readable by the computer.
`
`Claim 18 would appear to be directed to a method of pre(cid:173)
`paring a computer program.
`.
`According · to Rule 67.1 (V) and (VI) no International
`Preliminary Examination (thus no prelim~nary Written
`Opinion) can be carried out for such a subject matter.
`
`- _(le] the description, claims or drawings (indicate particular elements below) or said claims
`Nos. 16
`are so unclear that no seaninqful opinion could be formed
`---------------------------
`(spec if y):
`
`Claim 1 6 represents a novel claim-category; its subject
`matter is in fact a machine or an apparatus i.e. a com(cid:173)
`puter.
`Now an independent claim directed to a machine must cite
`all the essential technical features necessary to define
`said machine; the information saved in memory of a com(cid:173)
`puter are not considered a characterizing part of the
`same. Therefore the subject matter of claim 16 is
`definitely not at all characterized as requested by Art.
`
`Form PCT/IPEA/409 (sheet 2) (July 1992)
`
`139 of 1033
`
`BI Exhibit 1002
`
`

`

`•
`
`INTERNATIONAL PRELIMINARY EXAMINATION REPORT
`
`• Intern. application No.
`
`PCT/US92/05126
`
`6 PCT (see PCT Guideline~ C III 4.4).
`
`] the claims, or said claims Nos. - - - - - - - - - - - - - - are so inadequately supported by
`the description that no meaningful opinion could be for111ed.
`
`J no international search report has been established for said claiins ·
`Nos. --------------
`
`..:.
`
`. -: ........
`
`: ' .. - .
`
`-.
`
`. ·
`
`Form PCT/IPBA/409 (sheet 3) (July 1992)
`
`140 of 1033
`
`BI Exhibit 1002
`
`

`

`,
`
`Intern. application Ho.
`
`INTERNATIONAL PRELIMINARY EXAMINATION REPORT
`
`PCT/US92/051~6
`
`.
`v. Reasoned statement under Article 35(2) vith regard to novelty, iilventfve step and industrial applicability;
`citations and · explan~ions supportin9 such statenent
`
`'
`
`Claims 1-9, . 12-15, 19_· ________ YES
`Claims 10 1- ,.11 - . . -
`
`NO
`
`Claim,s 2, . ~-9,, J.~,. 14, _19
`. -
`~ !""'
`•,
`- - - - - -
`Claims 1, ~-:5, 12, 15
`: .. ..
`. .~ ~ . . - : . - ....
`.
`
`YES
`NO
`
`1. STATEMENT
`
`Novelty (N)
`
`Inventive Step (IS)
`
`Industrial Applicability (IA)
`
`2. CITATIONS AND EXPLANATIONS
`
`• • -.-;,
`
`lr11 ·.::.iJ:G "..:'
`
`_._ . · -·:""'
`
`Claims 1-1 9
`--------------
`Cl a i lllS - - - - -·-· ·- - - - - - - - - - - - - HO
`
`;· .. :-
`
`~ _
`
`YES
`
`1.
`
`The following document is referred to in the present
`IPER as the- closest prio~ art~
`
`WO-A-90/07861:
`
`..... .. ..: .
`
`1 - •
`
`-
`
`•
`
`••
`
`•
`
`•
`
`- •• - ; -
`
`-
`
`: :.. -
`
`• ~
`
`:
`
`.:. - t
`
`2.
`
`This. ear~ie~ application d~s~rip~s _ a _ method for design(cid:173)
`ing ·humani2ed antibodie~ whi~h consists of all the steps
`a) ~o g) of the present clai~ 1.
`
`More precisely . the features under item a) that the amino
`acid sequences of both donor.(import) arid acceptor (con(cid:173)
`sensus) antibody are from the variable domain and that
`the human sequence (acceptor) is a consensus sequence
`are disclosed at page 10, last two · lines· and' page · 11
`first- lines and: page 12 "criterion I.
`Steps under b) and c) are disclosed at page s line 8 to
`31 ·and claim 18.
`steps under items d) to g) are disclosed in claims 19 to
`21 and at page 5 line 32 to page 6 line 20 and more in
`details at page. 11 line 19 to page 15
`line 2.
`
`Form PCT/IPKA/409 (sheet 4) (July 1992)
`
`141 of 1033
`
`BI Exhibit 1002
`
`

`

`•
`
`INTERNATIONAL PRELIMINARY EXAMINATION .REPORT
`
`Intern. application Ho.
`
`PCT/U~92/05126
`
`Among the three criteria for sel~cting FR-residues con(cid:173)
`venrent for substitution (item f), criterion 2 . is dis(cid:173)
`closed at page 14 under "criterion IV" and criterion 1.
`is disclosed at page 14 lines 7 _ an~ _ 8.
`.
`.
`.
`
`2.1 Under "crite